Samuel Tekeste Workenhe

9PUBLICATIONS
23CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsMedical molecular engineering of nucleic acids and proteinsTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Oct 08, 2024
Level of Expression of MHCI-Presented Neoepitopes Influences Tumor Rejection by Neoantigen-Specific CD8+ T Cells.

Li Deng, Scott R Walsh, Andrew Nguyen

|Apr 05, 2024
Pyroptosis activates conventional type I dendritic cells to mediate the priming of highly functional anticancer T cells.

Jordon M Inkol, Michael J Westerveld, Shayla G Verburg

|Oct 30, 2023
Determinants for Antitumor and Protumor Effects of Programmed Cell Death.

Samuel T Workenhe, Jordon M Inkol, Michael J Westerveld

|Mar 23, 2023
Adaptation of transgene mRNA translation boosts the anticancer efficacy of oncolytic HSV1.

Huy-Dung Hoang, Aida Said, Nasana Vaidya

|Aug 11, 2022
Viral-mediated activation and inhibition of programmed cell death.

Shayla Grace Verburg, Rebecca Margaret Lelievre, Michael James Westerveld

Pageof 2